Perspectives on current directions in the neurobiology of addiction disorders relevant to genetic risk factors

CNS Spectrums

Volumn 11, Issue 11, 2006, Pages 855-862

  Hurd, Yasmin L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; NEUROPEPTIDE; OPIATE; OPIATE DERIVATIVE; PSYCHOSTIMULANT AGENT;

DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG DEPENDENCE; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; NEUROBIOLOGY; NEUROPSYCHIATRY; NEUROTRANSMISSION; OPIATE ADDICTION; PRIORITY JOURNAL; REVIEW; REWARD;

EID: 33751574915     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900015005     Document Type: Review

References (103)

1. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet. 2005;6:521-532.
2. Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 1998;55:967-972.
3. Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry. 1998;55:973-979.
4. Ungless MA. Dopamine: the salient issue. Trends Neurosci. 2004;27:702-706.
5. McClure SM, Daw ND, Montague PR. A computational substrate for incentive salience. Trends Neurosci. 2003;26:423-428.
6. Haber SN, Ryoo H, Cox C, Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol. 1995;362:400-410.
7. Zahm DS, Brog JS. On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience. 1992;50:751-767.
8. Groenewegen HJ, Wright CI, Beijer AV. The nucleus accumbens: gateway for limbic structures to reach the motor system? Prog Brain Res. 1996;107:485-511.
9. Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends Neurosci. 2004;27:270-277.
10. Hitri A, Hurd YL, Wyatt RJ, Deutsch SI. Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance. Clin Neuropharmacol. 1994;17:1-22.
11. Amara SG, Kuhar MJ. Neurotransmitter transporters: recent progress. Annu Rev Neurosci. 1993;16:73-93.
12. Vandenbergh DJ, Persico AM, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics. 1992;14:1104-1106.
13. Gelernter J, Kranzler H, Lacobelle J. Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 dopamine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor (OPRM1), and ciliary neurotrophic factor (CNTF)). Genomics. 1998;52:289-297.
14. Jacobsen LK, Staley JK, Zoghbi SS, et al. Prediction of dopamine transporter binding availability by genotype: a preliminary report. Am J Psychiatry. 2000;157:1700-1703.
15. Heinz A, Goldman D, Jones DW, et al. Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology. 2000;22:133-139.
16. Martinez D, Gelernter J, Abi-Dargham A, et al. The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology. 2001;24:553-560.
17. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology. 1994;11:195-200.
18. Liu HC, Lin SK, Liu SK, et al. DAT polymorphism and diverse clinical manifestations in methamphetamine abusers. Psychiatr Genet. 2004;14:33-37.
19. Hong CJ, Cheng CY, Shu LR, Yang CY, Tsai SJ. Association study of the dopamine and serotonin transporter genetic polymorphisms and methamphetamine abuse in Chinese males. J Neural Transm. 2003;110:345-351.
20. Guindalini C, Howard M, Haddley K, et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc Natl Acad Sci U S A. 2006;103:4552-4557.
21. Ujike H, Harano M, Inada T, et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J. 2003;3:242-247.
22. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci. 1992;12:483-488.
23. Gerra G, Garofano L, Pellegrini C, et al. Allelic association of a dopamine transporter gene polymorphism with antisocial behaviour in heroin-dependent patients. Addict Biol. 2005;10:275-281.
24. Galeeva AR Gareeva AE, Iur'ev EG, et al. VNTR polymorphisms of the serotonin transporter and dopamine transporter genes in male opiate addicts [Russian]. Mol Biol (Mosk). 2002;36:593-598.
25. Volkow ND, Fowler JS, Wang GJ, et al. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol Learn Mem. 2002;78:610-624
26. Nader MA, Morgan D, Gage HD, et al. PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. Nat Neurosci. 2006;9:1050-1056.
27. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ, et al. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism Arch Gen Psychiatry. 1991;48:648-654.
28. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet. 2003;116:103-125.
29. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23:540-545.
30. Persico AM, Bird G, Gabbay FH, Uhl GR, et al. D2 dopamine receptor gene Taql A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry. 1996;40:776-784.
31. Comings DE, Gonzalez N, Wu S, et al. Homozygosity at the dopamine DRD3 receptor gene in cocaine dependence. Mol Psychiatry. 1999;4:484-487.
32. Gelernter J, Kranzler H, Satel SL. No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. Biol Psychiatry. 1999;45:340-345
33. Lawford BR, Young RM, Noble EP, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet. 2000;96:592-598.
34. Shahmoradgoli Najafabadi M, Ohadi M, Jogbataie MT, et al. Association between the DRD2 A1 allele and opium addiction in the Iranian population. Am J Med Genet B Neuropsychiatr Genet. 2005;134:39-41.
35. Xu K, Lichtermann D, Lipsky RH, et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry. 2004;61:597-606.
36. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 1998;779:58-74.
37. Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A. 1994;91:11271-11275.
38. Chen J, Marmur R, Paredes W, Pulles A, Gardner EL. Systemic cocaine challenge after chronic cocaine treatment reveals sensitization of extracellular dopamine levels in nucleus accumbens but direct cocaine perfusion into nucleus accumbens does not: implications for the neural locus of cocaine sensitization. Life Sci. 1996;58:PL139-PL146.
39. Ebstein RP, Novick O, Umansky R, et al. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking. Nat Genet. 1996;12:78-80
40. Schinka JA, Letsch EA, Crawford FC. DRD4 and novelty seeking: results of meta-analyses. Am J Med Genet. 2002;114:643-648.
41. Lee HJ, Lee HS, Kim YK, et al. D2 and D4 dopamine receptor gene polymorphisms and personality traits in a young Korean population. Am J Med Genet B Neuropsychiatr Genet. 2003;121:44-49.
42. Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry. 1997;2:251-254.
43. Li T, Zhu ZH, Liu X, et al. Association analysis of polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. Am J Med Genet. 2000;96:616-621.
44. Li T, Xu K, Deng H, et al. Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects. Mol Psychiatry. 1997;2:413-416
45. Li T, Chen CK, Hu X, et al. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004;129:120-124.
46. Duaux E, Gorwood P, Griffon N, et al. Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry. 1998;3:333-336.
47. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction. 2001;96:103-114.
48. Li Y, Shao C, Zhang D, et al. The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese Am J Med Genet B Neuropsychiatr Genet. 2006;141:269-273.
49. Shao C, Li Y, Jiang K, et al. Dopamine D4 receptor polymorphism modulates cue-elicited heroin craving in Chinese. Psychopharmacology (Berl). 2006;186:185-190.
50. Herz A. Opioid reward mechanisms: a key role in drug abuse? Can J Physiol Pharmacol. 1998;76:252-258.
51. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66:285-306.
52. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav. 2002;76:365-377.
53. Pecina S, Berridge KC. Hedonic hot spot in nucleus accumbens shell: where do mu-opioids cause increased hedonic impact of sweetness? J Neurosci. 2005;25:11777-11786.
54. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction Proc Natl Acad Sci U S A. 1998;95:9608-9613.
55. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280:32618-32624.
56. Drakenberg K, Nikoshkov A, Horvath MC, et al. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers Proc Natl Acad Sci U S A. 2006;103:7883-7888
57. Bart G, Laforge KS, Borg L, Lilly C, Ho A, Kreek MJ. Altered Levels of Basal Cortisol in Healthy Subjects with a 118G Allele in Exon 1 of the Mu Opioid Receptor Gene. Neuropsychopharmacology. 2006;31:2313-2317.
58. Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans Am J Med Genet B Neuropsychiatr Genet. 2003;120:97-108.
59. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 2006;83:262-268.
60. Gelernter J, Kranzler H, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol-and drug-dependent subjects. Mol Psychiatry. 1999;4:476-483.
61. Crowley JJ, Oslin DW, Patkar AA, et al. A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet. 2003;13:169-173.
62. Franke P, Wang T, Nothen MM, et al. Nonreplication of association between muopioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet. 2001;105:114-119.
63. Szeto CY, Tang NL, Lee DT, Stadlin A. Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport. 2001;12:1103-1106.
64. Tan EC, Tan CH, Karupathivan U, Yap EP. Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport. 2003;14:569-572
65. Bart G, Heilig M, LaForge KS, et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden Mol Psychiatry. 2004;9:547-549.
66. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G. Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002;19:459-460.
67. Ide S, Kobayashi H, Tanaka K, et al. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. Ann N Y Acad Sci. 2004;1025:316-324
68. Comings DE, Blake H, Dietz G, et al. The proenkephalin gene (PENK) and opioid dependence. Neuroreport. 1999;10:1133-1135.
69. Hurd YL, Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993;13:357-369.
70. Staley JK, Rothman RB, Rice KC, Partilla J, Mash DC. Kappa2 opioid receptors in limbic areas of the human brain are upregulated by cocaine in fatal overdose victims. J Neurosci. 1997;17:8225-8233.
71. Zimprich A, Kraus J, Woltje M, Mayer P, Rauch E, Hollt V. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J Neurochem. 2000;74:472-477.
72. Chen AC, LaForge KS, Ho A, et al. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am J Med Genet. 2002;114:429-435.
73. Dahl JP, Weller AE, Kampman KM, et al. Confirmation of the association between a polymorphism in the promoter region of the prodynorphin gene and cocaine dependence. Am J Med Genet B Neuropsychiatr Genet. 2005;139:106-108.
74. Ray R, Doyle GA, Crowley JJ, et al. A functional prodynorphin promoter polymorphism and opioid dependence. Psychiatr Genet. 2005;15:295-298
75. Yuferov V, Fussell D, LaForge KS, et al. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics. 2004;14:793-804.
76. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-4210.
77. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98:6917-6922.
78. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci. 2004;8:325-335.
79. Joober R, Gauthier J, Lal S, et al. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry. 2002;59:662-663.
80. Blasi G, Mattay VS, Bertolino A, et al. Effect of catechol-O- methyltransferase val158met genotype on attentional control. J Neurosci. 2005;25:5038-5045.
81. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004;161:1798-1805.
82. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet. 1997;74:439-442.
83. Horowitz R, Kotler M, Shufman E, et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet. 2000;96:599-603.
84. Biederman J, Wilens T, Mick E, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36:21-29.
85. Flory K, Lynam DR. The relation between attention deficit hyperactivity disorder and substance abuse: what role does conduct disorder play? Clin Child Fam Psychol Rev. 2003;6:1-16.
86. Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1052-1057.
87. Chen CK, Hu X, Lin SK, et al. Association analysis of dopamine D2-like receptor genes and methamphetamine abuse. Psychiatr Genet. 2004;14:223-226.
88. Goldman-Rakic PS, Muly EC 3rd, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000;31:295-301.
89. Williams GV, Castner SA. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience. 2006;139:263-276.
90. Ciccocioppo R, Sanna PP, Weiss F. Cocaine-predictive stimulus induces drug-seeking behavior and neural activation in limbic brain regions after multiple months of abstinence: reversal by D(1) antagonists. Proc Natl Acad Sci U S A. 2001;98:1976-1981.
91. Hummel M, Unterwald EM. D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action. J Cell Physiol. 2002;191:17-27.
92. Comings DE, Gade R, Wu S, et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry. 1997;2:44-56.
93. Liu HC, Chen CK, Leu SJ, Wu HT, Lin SK. Association between dopamine receptor D1 A-48G polymorphism and methamphetamine abuse. Psychiatry Clin Neurosci. 2006;60:226-231.
94. Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991;350:614-619.
95. Sherrington R, Mankoo B, Attwood J, et al. Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomics. 1993;18:423-425
96. Vanyukov MM, Moss HB, Gioio AE, Hughes HB, Kaplan BB, Tarter RE. An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. Behav Genet. 1998;28:75-82.
97. Vanyukov MM, Moss HB, Kaplan BB, Kirillova GP, Tarter RE. Antisociality, substance dependence, and the DRD5 gene: a preliminary study. Am J Med Genet. 2000;96:654-658.
98. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol. 1998;54:679-720.
99. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403-1413.
100. Szumlinski KK, Abernathy KE, Oleson EB, et al. Homer isoforms differentially regulate cocaine-induced neuroplasticity. Neuropsychopharmacology. 2006;31:768-777.
101. Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED. ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem. 2002;81:903-910.
102. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS. PSD-95 involvement in maturation of excitatory synapses. Science. 2000;290:1364-1368.
103. Szumlinski KK, Kalivas PW, Worley PF. Homer proteins: implications for neuropsychiatric disorders. Curr Opin Neurobiol. 2006;16:251-257.